4'-O-methylbavachalcone alleviates ischemic stroke injury by inhibiting parthanatos and promoting SIRT3

Eur J Pharmacol. 2024 Jun 5:972:176557. doi: 10.1016/j.ejphar.2024.176557. Epub 2024 Apr 3.

Abstract

Cerebral ischemia-reperfusion injury (CIRI) can induce massive death of ischemic penumbra neurons via oxygen burst, exacerbating brain damage. Parthanatos is a form of caspase-independent cell death involving excessive activation of PARP-1, closely associated with intense oxidative stress following CIRI. 4'-O-methylbavachalcone (MeBavaC), an isoprenylated chalcone component in Fructus Psoraleae, has potential neuroprotective effects. This study primarily investigates whether MeBavaC can act on SIRT3 to alleviate parthanatos of ischemic penumbra neurons induced by CIRI. MeBavaC was oral gavaged to the middle cerebral artery occlusion-reperfusion (MCAO/R) rats after occlusion. The effects of MeBavaC on cerebral injury were detected by the neurological deficit score and cerebral infarct volume. In vitro, PC-12 cells were subjected to oxygen and glucose deprivation/reoxygenation (OGD/R), and assessed cell viability and cell injury. Also, the levels of ROS, mitochondrial membrane potential (MMP), and intracellular Ca2+ levels were detected to reflect mitochondrial function. We conducted western blotting analyses of proteins involved in parthanatos and related signaling pathways. Finally, the exact mechanism between the neuroprotection of MeBavaC and parthanatos was explored. Our results indicate that MeBavaC reduces the cerebral infarct volume and neurological deficit scores in MCAO/R rats, and inhibits the decreased viability of PC-12 cells induced by OGD/R. MeBavaC also downregulates the expression of parthanatos-related death proteins PARP-1, PAR, and AIF. However, this inhibitory effect is weakened after the use of a SIRT3 inhibitor. In conclusion, the protective effect of MeBavaC against CIRI may be achieved by inhibiting parthanatos of ischemic penumbra neurons through the SIRT3-PARP-1 axis.

Keywords: 4′-O-Methylbavachalcone; Ischemic stroke; PARP-1; Parthanatos; SIRT3.

MeSH terms

  • Animals
  • Calcium / metabolism
  • Cell Survival / drug effects
  • Chalcones* / pharmacology
  • Chalcones* / therapeutic use
  • Infarction, Middle Cerebral Artery / complications
  • Infarction, Middle Cerebral Artery / drug therapy
  • Infarction, Middle Cerebral Artery / pathology
  • Ischemic Stroke / drug therapy
  • Ischemic Stroke / metabolism
  • Ischemic Stroke / pathology
  • Male
  • Membrane Potential, Mitochondrial / drug effects
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Neurons / drug effects
  • Neurons / metabolism
  • Neurons / pathology
  • Neuroprotective Agents* / pharmacology
  • Neuroprotective Agents* / therapeutic use
  • PC12 Cells
  • Parthanatos* / drug effects
  • Poly (ADP-Ribose) Polymerase-1 / antagonists & inhibitors
  • Poly (ADP-Ribose) Polymerase-1 / metabolism
  • Rats
  • Rats, Sprague-Dawley*
  • Reactive Oxygen Species / metabolism
  • Reperfusion Injury* / drug therapy
  • Reperfusion Injury* / metabolism
  • Reperfusion Injury* / pathology
  • Sirtuin 3 / genetics
  • Sirtuin 3 / metabolism
  • Sirtuins*

Substances

  • Chalcones
  • Neuroprotective Agents
  • Reactive Oxygen Species
  • SIRT3 protein, rat
  • Calcium
  • Sirtuin 3
  • Poly (ADP-Ribose) Polymerase-1
  • Sirtuins